Hefei Hengxin Life Science and Technology
301501
Triductor Technology
688259
Zhejiang Sf Oilless Bearing Co.,Ltd.
300817
Shenzhen Riland Industry Group
300154
Chengdu TangYuan Electric
300789
CN Stock MarketDetailed Quotes
603127 Joinn Laboratories
- 22.32
- -0.32-1.41%
Market Closed Mar 19 15:00 CST
16.73BMarket Cap-22320.00P/E (TTM)
22.80High22.26Low79.82KlotVolume22.30Open22.64Pre Close179.32MTurnover1.27%Turnover Ratio42.11P/E (Static)749.48MShares23.4852wk High2.09P/B14.07BFloat Cap12.1652wk Low24.90Limit Up630.48MShs Float92.24Historical High20.38Limit Down2.39%Amplitude1.45Historical Low0.16Dividend TTM22.46Avg Price45.69KlotAsk0.72%Div YieldTTM100Lot Size31.00KlotBid
Joinn Laboratories News
Is the CRO Concept "Return of the King"? WuXi AppTec aggressively attacks, leading stocks celebrate after performance!
Release the signal?!
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Joinn Laboratories (06127.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.
Gelonghui announced on March 14 that Joinn Laboratories (06127.HK) will hold a Board of Directors meeting on March 28, 2025 (Friday) to review and approve the group's annual performance for the year ending December 31, 2024, consider recommending a final dividend (if any), and address other matters.
JOINN Laboratories Schedules Board Meeting to Review Annual Results
JOINN: DATE OF BOARD MEETING
Hong Kong stock movement | Joinn Laboratories (06127) rose over 7% in the final hours as the potential of AI in pharmaceuticals is released, likely empowering the company's non-clinical research on drugs.
Joinn Laboratories (06127) surged over 7% in the late trading session, up 6.7% as of the time of writing, trading at 14.98 Hong Kong dollars, with a transaction amount of 33.8677 million Hong Kong dollars.
GTJA: AI technology drives efficiency innovation and optimizes the entire R&D chain of the CXO industry.
The penetration of AI technology accelerates the paradigm shift in the CXO industry. The deep application of AI technology in the Biomedical field is expected to reconstruct the value chain of the CXO industry.
Joinn Laboratories (06127.HK): As of February 28, a total of 3.2698 million A-shares have been repurchased.
On March 3, Gelonghui reported that Joinn Laboratories (06127.HK) announced that as of February 28, 2025, the company has cumulatively repurchased 3.2698 million A-shares through centralized bidding, accounting for 0.4363% of the total shares as of the announcement date. The maximum repurchase price was 18.15 yuan per share, the minimum repurchase price was 13.20 yuan per share, and the total amount of funds used was 52.992 million yuan (excluding transaction fees).
Trending Industry Today: WUXI BIO Leads Losses In CRO Stocks
Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected
Trending Stocks Today: MINTH GROUP Surges 28.86%
Hong Kong stocks movement | Most CRO Concept stocks rose, and the Industry is expected to enter a stable growth phase. AI pharmaceutical technology and others are worth paying attention to.
Most CRO Concept stocks rose. As of the time of writing, Joinn Laboratories (06127) increased by 14.89% to 12.5 HKD; TIGERMED (03347) rose by 13.17% to 35.65 HKD; Asymchem Laboratories (06821) went up by 5.75% to 58.85 HKD.
Contract Research Organizations concept stocks showed strong performance in early trading, with TIGERMED (03347) up 8.41%. Institutions indicate that the Industry is expected to enter a stable growth phase this year.
Jinwu Finance | Stocks in the Contract Research Organizations sector opened strong. As of the time of writing, TIGERMED (03347) rose 8.41%, Joinn Laboratories (06127) rose 6.62%, PHARMARON (03759) rose 6.22%, Asymchem Laboratories (06821) rose 4.4%, and WUXI APPTEC (02359) rose 2.81%. On the news front, GTJA released a Research Report stating that after experiencing disturbances from multiple factors such as financing disruption, high base from COVID-19, price war competition, and geopolitical disturbances, the current adjustment is nearing its end. In the medium term, technological innovation and upgrades, along with AI, will assist in the drug discovery phase.
Joinn Laboratories (06127.HK) received an increase in shareholding of 0.0443 million shares from E Fund.
On February 19, according to the latest equity disclosure information from the Stock Exchange, on February 13, 2025, Joinn Laboratories (06127.HK) saw E Fund Management Co., Ltd. increase its shareholding by 0.0443 million shares at an average price of HKD 9.9953 per share, involving approximately HKD 0.4428 million. After this shareholding increase, E Fund Management Co., Ltd.'s latest number of shares held is 5.9725 million shares, with its shareholding ratio rising from 4.98% to 5.02%.
GTJA: The new paradigm reshapes the drug development landscape, and the cycle of inventory reduction for Active Pharmaceutical Ingredient is approaching its end.
The CXO adjustments are nearing completion, and the Industry is moving towards the development stage 2.0; the API destocking cycle is coming to an end, seizing opportunities for industrial transformation.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Joinn Laboratories (603127.SH): A total buyback of 0.4363% of A-shares.
On February 6, Gelonghui reported that Joinn Laboratories (603127.SH) announced that as of January 31, 2025, the company has cumulatively repurchased 3,269,820 A-shares through centralized auction trading, accounting for 0.4363% of the company's total shares on the announcement date, with the highest repurchase price being 18.15 RMB/share, the lowest repurchase price being 13.20 RMB/share, and the total amount of funds used being 52,991,757.40 RMB (excluding transaction costs).
Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Market Cap up CN¥645m Last Week, Benefiting Both Retail Investors Who Own 41% as Well as Insiders
Joinn Laboratories (China) Warns of Up to 85% Profit Slump in 2024
